SPR® Therapeutics is proud to share that over 30,000 patients have now been treated with the SPRINT PNS System. The rapid adoption of SPRINT PNS as an option to address a variety of painful conditions throughout the body has led to significant commercial acceleration over the last year when the company announced the 20,000th treatment. Within the past year, publications and studies have featured the use of SPRINT for pain following knee replacement, shoulder pain, headache and neck pain, groin pain, and complex regional pain syndrome (CRPS) in addition to well-established use throughout the body. This commitment to research and development is driven by the continued interest from both physicians and patients for a minimally invasive, short-term, nonopioid treatment with a strong safety profile.
“We are proud of the continued impact of SPRINT PNS in the market to support our physician partners, but even more meaningful is the opportunity to help patients that have struggled with and lived with pain,” said Maria Bennett, President, CEO and Founder of SPR Therapeutics. “There is a story to each of the 30,000 treatments and those are at the heart of why we work every day to continually improve access and ensure patients can benefit from the right treatment to address their pain.”
To learn more about the life-changing difference the SPRINT PNS System continues to make in the lives of those living with pain, please visit our Patient Stories page. Some patients lived with pain for decades and others missed out on the moments in life that make it worth living but finding relief from pain has given them back their independence and the ability to pursue their passions.
SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
Leave a Reply